A drug used to treat cardiac failure has shown promising results in treating triple-negative breast cancer.
The 51.5% year-on-year growth in India’s pharmaceutical market during April was led by a low base effect as the market declined by 10.2% in April 2020 due to Covid-19 lockdown, as per India Ratings and Research (Ind-Ra).
The growth would have been stronger on an adjusted basis, it said. Acute therapies like anti-infective and vitamins benefitted significantly due to the second Covid wave as these therapies have a direct and indirect role in the treatment of patients. The acute therapy growth was also aided by a low base in April last year, said Ind-Ra.
During April 2021, volumes grew 34.5% YoY, price growth was 7% and product launches were at 10% attributed to acute therapy products. Ind-Ra estimated the market growth of 8% to 10% YoY during FY22.
ANI
Kenya sends more officers to Haiti, reinforcing efforts to curb gang violence that has displaced…
Yoon Suk Yeol's detention was extended due to fears of evidence destruction in a martial…
The new underground missile base, capable of launching cruise missiles from advanced speedboats, underscores Iran's…
Iranian state media reports the judges were shot by an assailant who later took his…
In Chihuahua, migrants set mattresses ablaze in response to a raid aimed at clearing the…
Kennedy's petition to halt vaccine approval in 2021 sparked controversy, advocating against mRNA vaccines and…